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 Abstract 
 
Objective: 
Individual studies have reported conflicting effects of selective serotonin reuptake 
inhibitors (SSRIs) on glycaemia. We systematically reviewed the effects of SSRIs on 
glycemia and whether metabolic and psychological factors moderated these effects. 
 
Methods:  
We systematically searched for placebo-controlled randomised controlled trials (RCTs) 
investigating the effect of SSRIs on glycaemia (fasting blood glucose or HbA1c) as a 
primary or secondary outcome. Random-effects meta-analysis was conducted to 
compute an overall treatment effect. Meta-regression tested whether depression, type 2 
diabetes, insulin resistance, treatment duration and weight loss moderated treatment 
effects.  
 
Results:  
Sixteen RCTs (n=835) were included and glycaemia was usually a secondary outcome. 
Overall, SSRIs improved glycaemia versus placebo (pooled effect size (ES)=-0.34, 95% 
confidence interval (CI) -0.48 to -0.21; p < 0.001, I
2
=0%). Individually, fluoxetine 
(ES=-0.29, 95% CI -0.54 to -0.05; p=0.018) and escitalopram/citalopram (ES=-0.33, 
95% CI -0.59 to -0.07; p=0.012) outperformed placebo, but paroxetine (ES=-0.19, 95% 
CI -0.58 to 0.19; p=0.33) did not. Results were similar in populations selected for 
depression as those not. Across studies, baseline insulin resistance (p=0.46), treatment 
duration (p=0.47), diabetes status (p=0.41) and weight loss (p=0.93) did not moderate 
changes. Heterogeneity for all analyses was non-significant.  
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 Conclusions:  
SSRIs appear to have an association with improvement in glycaemia, which is not 
moderated by depression status, diabetes status or change in weight across studies. 
Future powered trials with longer treatment duration are needed to confirm these 
findings. 
 
Registration: 
PROSPERO ID: CRD4201809239 
 
Keywords: 
Diabetes; depression; insulin resistance; systematic review, meta-analysis, meta-
regression. 
 
Abbreviations: 
CI = confidence interval; ES = effect size; HOMA = Homeostatic Model Assessment; 
RCT = randomised controlled trial; SMD = standardised mean difference; SSRI = 
selective serotonin reuptake inhibitors. 
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 Introduction 
Depressive symptoms are twice as common in people with type 2 diabetes compared to 
the general population and are associated with increased risk of diabetes complications 
and premature mortality (1, 2). The selective serotonin reuptake inhibitors (SSRIs) class 
of antidepressants are recommended as first-line pharmacotherapy for depression (3), as 
they are considered to have a favourable side effect profile. The effects of SSRIs are less 
well established in type 2 diabetes; while SSRIs consistently improve depressive 
outcomes (4), the evidence that they improve glycaemia and other biomedical outcomes 
is less consistent. A recent systematic review of observational studies reported that 
antidepressant use may in fact increase the risk of incident type 2 diabetes (5), although 
the causal basis of this association has been disputed (6). In randomised controlled trials 
(RCTs) of patients with type 2 diabetes and depression, some have reported benefits of 
SSRIs on both depression and glycaemia, whereas others have reported benefit for 
depression but not glycaemia (7).  
 
A potential reason for the inconsistency in findings is the different types of SSRIs used. 
RCTs that have tested fluoxetine versus placebo have generally found improvements in 
glycaemia (8, 9), whereas other SSRIs such as paroxetine have not observed such 
positive effects (10). No previous meta-analysis has compared different types of SSRI for 
their effects on glycaemia. Another possible reason is different clinical groups: whilst 
some studies have tested SSRIs for glycaemia in patients with comorbid depression (7), 
others have not selected for depression (8, 9). Some studies have recruited non-diabetes 
patients with elevated insulin resistance (11), whilst others have recruited patients with 
established diabetes (12). Within the type 2 diabetes population, study samples have 
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 varied from those who are insulin-requiring (13) to those still prescribed only oral 
diabetes medications (12).  
 
With SSRIs proposed as both a potential cause and a potential therapy for diabetes, a 
clearer consensus regarding their effects on glycaemia is needed, as well as the 
metabolic and psychological moderators of such effects. We have therefore conducted a 
systematic review and meta-analysis of placebo-controlled RCTs, with the primary aim 
of testing whether SSRIs cause a change in glycaemia over time. Our secondary aims 
were to compare individual SSRIs for their respective effects on glycaemia, and to test 
for moderators of response, including comorbidity of depression, comorbidity of 
diabetes, elevated insulin resistance, treatment duration and weight loss.  
 
Methods 
Search strategy and selection criteria 
The current systematic review followed the Preferred Reporting Items for Systematic 
Reviews and Meta-Analyses (PRISMA) guidelines (14), in which studies that meet 
review criteria are examined and those that were RCTs and with sufficient data pooled 
for meta-analysis. The protocol was prospectively registered (PROSPERO ID 
CRD42018092397) (15). 
 
We systematically searched the following databases from 1 January 1987 (as 
contemporary SSRIs were first used in this year) to 28 March 2018: EMBASE, 
PsycINFO, Web of Science, Cochrane Central Register of Controlled Trials (CENTRAL) 
and PubMed. Additionally, unpublished trials were searched for in clinical trials 
databases such as ClinicalTrials.gov and the ISRCTN Register.  
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 The following MeSH search strategy was implemented: “("Serotonin Uptake 
Inhibitors/blood"[Mesh] OR "Serotonin Uptake Inhibitors/therapeutic use"[Mesh]) AND 
("Diabetes Mellitus, Type 2/drug therapy"[Mesh] OR "Diabetes Mellitus, Type 
2/metabolism"[Mesh] OR "Diabetes Mellitus, Type 2/prevention and control"[Mesh] OR 
"Diabetes Mellitus, Type 2/psychology"[Mesh] OR "Diabetes Mellitus, Type 
2/therapy"[Mesh])”. Following this, a free text search was carried out in all databases 
using Boolean operators and truncation (*): “(ssri* OR "selective serotonin" OR 
fluoxetine OR citalopram OR escitalopram OR fluvoxamine OR sertraline OR 
paroxetine) AND (glycaemic OR glycemic OR glycaemia OR glycemia OR glucose OR 
diabetes OR diabetic OR "insulin resistance" OR "insulin sensitivity" OR "insulin 
secretion" OR "beta-cell function" OR homa-ir OR homa-b OR "metabolic factors") NOT 
(rat* OR mouse OR mice)”. Where filters could be applied appropriately, the search was 
limited to clinical trials and human studies only. 
 
Titles were reviewed and abstracts of all titles fulfilling the inclusion criteria were 
assessed. Full-text articles of abstracts meeting the inclusion criteria were examined and 
relevant studies were analysed for data extraction. The reference lists of included studies 
were checked for additional publications. Two authors (TT and CDM) independently 
performed the literature search and evaluated the studies for inclusion. Any 
disagreements were resolved through discussion with a third author (CWPH) and 
consensus reached.  
 
The inclusion criteria were: (1) RCTs comparing any SSRIs with placebo, (2) glycaemia 
was measured, as a primary or a secondary outcome, using HbA1c or fasting blood 
glucose (FBG), (3) glycaemia was measured before and after the intervention and 
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 placebo, (4) a minimum of 10 patients were recruited. The specific exclusion criteria 
were: (1) observational studies, (2) case reports or case series, (3) review articles or other 
secondary analyses not presenting original data, (4) pre-clinical studies performed in vitro 
or in animals, (5) RCTs involving active controls such as other antidepressants. 
 
To maximise comparability of studies and to account most robustly for placebo effects on 
depression, only placebo-controlled RCTs were included. We included a range of studies 
examining patients with type 2 diabetes, patients without type 2 diabetes, as well as 
patients with and without depression, in order to elicit the impact of SSRIs on different 
subpopulations. However, because potential effects of SSRIs on insulin secretion were 
evaluated, we additionally excluded studies involving exclusively patients with type 1 
diabetes or exclusively insulin-dependent type 2 diabetes, given that their endogenous 
insulin secretory function has a limited chance of recovery with pharmacotherapy (16). 
 
Data extraction and quality assessment 
The primary outcome was change in glycaemia, as measured by FBG or HbA1c. As FBG 
is more rapidly responsive to change (17), this was used as the primary data of extraction 
where presented. For each included study, the following additional data were extracted: 
sample size, mean age and sex of participants, baseline diabetes/metabolic status 
(including baseline insulin resistance and insulin secretion estimates), duration and dose 
of intervention and control, baseline BMI and change in weight, significant adverse 
effects, whether glycaemia was a primary or secondary outcome, and the mean change in 
FBG for intervention and control groups. If the raw value for mean change in FBG was 
not presented, this was estimated by subtracting baseline FBG from follow-up FBG. If 
the SD of the change score was missing, we used the square root of the average of the 
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 baseline and follow-up variance in each group, thereby assuming that the correlation 
between the baseline and the follow-up outcome values was 0.5. If raw values for insulin 
resistance and secretion were not available, the Homeostatic Model Assessment (HOMA) 
formula (18), which uses FBG and fasting plasma insulin, was employed to derive these 
values. For studies including a subgroup of patients with insulin-dependent diabetes, the 
authors were contacted for data stratified by insulin use. If no response was received, the 
whole sample was included in order to extract the maximum available data.  
 
The quality of studies was evaluated using the Cochrane Collaboration‟s tool for risk of 
bias (19). Whilst other quality assessment tools are numerical scales, empirical evidence 
suggests associations between such scales and treatment effect sizes are inconsistent and 
unpredictable (20). For each type of bias, two authors (TT and CWPH) independently 
judged the risk as low, high or unclear using the Cochrane Collaboration tool‟s criteria. 
Consensus discussion with a third author (CDM) was used to resolve differences. 
 
Statistical analysis  
Using the metan command in STATA 11.0, we performed meta-analysis for any 
individual SSRI tested in at least 3 RCTs. For each study, effect-size estimates were 
calculated using the standardised mean difference (SMD) in change in glycaemia 
following treatment. SMD is an appropriate measure of effect estimate when studies 
assess the same variable using different measures, such as FBG and HbA1c. SMD was 
calculated by dividing the mean difference by the pooled SD of each arm (equivalent to 
Cohen‟s d). Given that Cohen‟s d may produce a biased estimate of effect size in small 
studies where n < 20, this was converted into Hedges‟ g. The standard error (SE) of each 
study‟s group sizes was calculated according to a formula provided by Cooper and 
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 Hedges (21). Next, studies were weighted using an inverse-variance method, studies 
with larger precision given greater weight. Pooled effect estimates were calculated using 
a random-effects model, which allows for heterogeneity between studies by permitting 
the true effects estimated by the studies to differ between studies. The combined effect 
thus represents the mean of the population of true effects and is appropriate where 
effects may vary between populations (22). This is expected in this meta-analysis where 
there is variation in medication, metabolic status, treatment duration and dose.  
 
Forest plots were stratified firstly by type of SSRI, and citalopram and escitalopram 
were combined because of their similar molecular structure, as in previous meta-
analyses (23). In order to define subgroups most likely to respond to treatment, the meta-
analysis was repeated when stratified by presence/absence of depression and then 
presence/absence of diabetes at baseline. Heterogeneity between studies was quantified 
by calculating the I
2
 statistic, which represents the fraction of variation between studies 
attributable to heterogeneity. Values for I
2
 range between 0% and 100% with values of 
25%, 50% and 75% suggesting low, moderate and high heterogeneity respectively (24).  
 
Four independent sensitivity analyses were conducted: i) removing studies reporting 
HbA1c only; ii) removing studies involving any insulin-dependent patients; iii) 
removing studies reporting depression as a secondary outcome; and iv) removing small 
studies (recruiting less than 40 patients). Publication bias was assessed using a Funnel 
plot, Begg‟s Test and Egger‟s test (25). In order to define moderators of treatment 
response, we performed random-effects meta-regression using the following study-level 
covariates: baseline HOMA-IR (insulin resistance), baseline BMI, depression measured 
as a primary or secondary outcome (dummy coded 1 for primary, 0 for secondary), 
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 diabetes status (dummy coded 1 for diabetes population, 0 for non-diabetes), treatment 
duration in weeks, and change in body weight. Baseline HOMA-B is directly 
proportional to HOMA-IR so was not also tested in meta-regression. Data on change in 
HOMA measures were only available for 3 studies and therefore were not used. 
 
Results 
A total of 2761 potentially relevant studies were identified. After reviewing titles, 105 
abstracts were read and 42 full-texts further analysed. From these, 16 studies were 
included in meta-analysis (Figure 1), of which 8 (8, 9, 12, 26-30), 3 (10, 31, 32), 2 (11, 
33), 1 (34), 1 (35) and 1 (36) studies tested fluoxetine, paroxetine, escitalopram, 
citalopram, sertraline and fluvoxamine respectively. Duration of studies ranged from 4 
weeks to 12 months. Across all studies included in the meta-analysis, there were a total 
of 835 participants, with a mean age of 49.0 years and 47.1% of participants were male. 
Ten of the studies investigated patients with type 2 diabetes, of which 5 studies had 
comorbid depression. Only 4 studies measured glycaemia as a primary or co-primary 
outcome (10, 31, 34, 35). The majority of studies measured glycaemia using FBG and 
only 3 measured HbA1c (28, 32, 35) (Table 1). Risk of bias was low in most domains, 
excepting a high risk of attrition bias in 7 studies due to non-specification of intention-
to-treat analysis, an unclear risk of selection bias in 10 studies due to lack of detailed 
explanation of allocation concealment procedures, and an unclear bias arising from 
pharmaceutical funding for 8 of the studies (Table 2). Aside from an increased incidence 
of tremor in one study, adverse effects were no more common in SSRI patients than 
placebo (26) (Table 3). 
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 In the overall meta-analysis, SSRIs led to a significantly greater improvement in 
glycaemia compared to placebo (pooled effect size (ES) = -0.34, 95% CI -0.48 to -0.21; 
p < 0.001, Nstudies = 16). The overall heterogeneity for the full meta-analysis was very 
low (I
2 
= 0%, p = 0.63). Of individual SSRIs, a beneficial effect of SSRIs was observed 
for fluoxetine (ES = -0.29, 95% CI -0.54 to -0.05; p = 0.018) and 
escitalopram/citalopram (ES = -0.33, 95% CI -0.59 to -0.07; p = 0.012). In contrast, 
paroxetine displayed a non-significant effect on glycaemia (ES = -0.19, 95% CI -0.58 to 
0.19; p = 0.33). The heterogeneity for all subgroups was low and not significant. There 
were insufficient studies to perform a subgroup analysis on sertraline and fluvoxamine 
(Table 3, Figure 2).  
 
In the subgroup of patient with diabetes at baseline, SSRIs significantly improved 
glycaemia compared to placebo (ES = -0.40 (95% CI -0.60, -0.21), p < 0.001, Nstudies = 
10). However, in non-diabetes populations, this effect was not significant (ES = -0.26 
(95% CI -0.52, 0.01), p = 0.061, Nstudies = 6) (Table 3, Figure 3). Similar effects of SSRI 
were seen in patients with depression (ES = -0.31 (95% CI -0.57, -0.06), p = 0.015, 
Nstudies = 5) and those without depression (ES = -0.35 (-0.53, -0.18), p < 0.001, Nstudies = 
11) at baseline (Table 3, Figure 4). In random-effects meta-regression using study-level 
covariates, presence of diabetes (p= 0.41, Nstudies = 16) baseline HOMA-IR (p = 0.46, 
Nstudies = 7), baseline BMI (p = 0.30, Nstudies  = 12), duration of treatment (p=0.47, Nstudies 
= 16),  measuring depression as a primary or secondary outcome (p=0.87, Nstudies = 16), 
and change in weight (p = 0.93, Nstudies = 12) were not significantly associated with 
glycaemia treatment effect.  
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 In sensitivity analyses, when respectively excluding studies reporting HbA1c; studies 
including any insulin-dependent patients; studies measuring depressive symptoms as a 
secondary outcome; or studies with less than 40 patients, the overall result did not 
significantly differ (Supplementary Table 1, Supplemental Digital Content, 
http://links.lww.com/PSYMED/A567). There was no evidence of publication bias: 
(Egger‟s test p = 0.48, symmetrical Funnel plot (Figure 5), Begg‟s test p = 0.50).  
 
Discussion  
In this systematic review and meta-analysis of 16 RCTs, SSRIs had a positive overall 
effect on glycaemia compared to placebo. Of individual SSRIs, significant benefit was 
seen for fluoxetine and escitalopram/citalopram but not for paroxetine. The comorbidity 
of depression did not moderate the effects of SSRIs on glycaemia. SSRIs were generally 
well tolerated. Across studies, diabetes status, baseline insulin resistance, baseline BMI 
and change in weight were not associated with reduction in glycaemia in the treatment 
group, although between-study heterogeneity was very low.  
 
Comparison with previous literature 
Two previous systematic reviews have tested the effects of SSRIs on glycaemia. 
Although well conducted, both were significantly limited by their scope, including only 5 
studies each in their meta-analyses of SSRIs and glycaemia. The first included only 
fluoxetine studies (37), thereby excluding the majority of SSRIs, including those 
potentially more effective in treating depression (38). The second review was limited to 
patients with diagnosed depression and comorbid diagnosed diabetes (39), thereby 
excluding high-risk populations such as patients with obesity, who may also benefit from 
effects of SSRIs on glycaemia. By including 16 studies, our meta-analysis exhibits 
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 increased power for testing the effects of SSRIs on glycaemia. Moreover, this is the first 
meta-analysis to compare the different SSRIs and include studies investigating patients 
without diabetes, or without depression, in order to assess generalisability. 
 
Our findings contrast those of a systematic review of 22 observational studies of anti-
depressants and diabetes, which concluded, of antidepressants, “caution is advised and a 
heightened alertness to the potential risk of diabetes is necessary” (40). However, the 
authors stressed that causality was not established and pointed out large inconsistencies 
across studies. Likewise, secondary analyses of the Diabetes Prevention Program have 
reported an association between antidepressant use and increased risk of incident type 2 
diabetes (41). However, those receiving antidepressants at baseline had significantly 
higher CRP concentration (42), itself a robust risk factor for type 2 diabetes onset (43). 
This suggests that antidepressants are being given to people who are already at high risk 
of type 2 diabetes for other reasons. Whilst medical records studies have found evidence 
of weight gain following long-term use of some antidepressants (4), results of clinical 
trials have been conflicting and have consistently found weight-loss following  
fluoxetine treatment, at least in the short-term (45). Meanwhile, negative basic science 
experiments have generally used vastly supra-physiological concentrations of SSRIs, 
such that toxic effects on beta-cells are unsurprising. Thus, there have been reports that 
SSRIs such as fluoxetine impair -cell metabolic coupling and/or insulin secretion in 
vitro (46, 47), but fluoxetine concentrations up to 100M were used in these studies, 
considerably higher than the fluoxetine steady state concentration in plasma of 0.3-
2.6M (48). By contrast, basic science research using physiological concentrations of 
SSRIs has indicated that fluoxetine has direct peripheral effects stimulatory effects on 
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 mouse and human islets in vitro to increase insulin secretion and improve -cell mass 
(49). 
 
Interpretation 
Our findings suggest that short-term use of SSRIs is metabolically safe and may even 
improve glycaemic control. With 8 included studies, results for fluoxetine are the most 
rigorous. Out of the other SSRIs, only escitalopram/citalopram had a positive overall 
effect, although this is cautioned by a lower number of studies. Though likewise limited 
in power to detect a significant effect, the raw effect size (-0.19) for paroxetine was 
notably less promising, although the inclusion of some insulin-dependent patients in 2 of 
the 3 studies may have blunted this effect (10, 31). However, given that glycaemia was 
generally a secondary outcome of included studies, future trials are needed that are 
powered specifically for this measure and thereby confirm our findings. The relative 
paucity of data for non-fluoxetine SSRIs emphasises the need for trials of these agents 
for glycaemia. In particular, sertraline is commonly used for depression and positive 
effects on glycaemia have been reported by other clinical trials and some basic science 
research (50, 51).  
 
Although benefits on glycaemia were not significant in patients without established 
diabetes in our analysis, such effects were limited by a lower number of studies for non-
diabetes samples, which were also generally of shorter duration. Furthermore, their 
better glycaemia at baseline may have led to a floor effect in treatment response. 
Therefore, there is a need for 6-12-month trials of SSRIs targeted at patients at a high 
risk of diabetes.  
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 Of the possible mechanisms by which SSRIs could improve glycaemia, weight loss – 
itself a consistent finding in our analysis – did not correlate with improvement in 
glycaemia across studies. An alternative explanation is that improved glycaemia resulted 
from increased insulin secretion following SSRI treatment. In this case, greater benefit 
may be achieved by targeting patients with established diabetes: unlike patients with 
pre-diabetes, whose insulin secretion is largely preserved, patients with established 
diabetes exhibit markedly reduced insulin secretion (52), whose improvement is the 
target of medications such as sulphonylureas. Our results suggest that SSRIs could have 
a similar role in augmenting insulin secretion in patients with non-insulin-dependent 
diabetes. This requires further research by future studies using repeated measures of 
insulin function in tandem with measures of glycaemia. Although findings did not vary 
significantly whether patients were selected for depression or not, there were fewer 
studies recruiting patients with depression in our synthesis. Therefore, it remains 
conceivable that some effects could occur through improvement in depression leading to 
improved self-care, treatment adherence and physical activity. Further studies targeting 
patients with depression are needed to test this model. 
 
Strengths and limitations 
Our review is strengthened by its systematic literature search, combined data collection 
on glycaemia measures and biological correlates, and the use of random-effects meta-
analysis to account for heterogeneity. Including 16 studies enabled us for the first time 
to compare different SSRIs, to test effects on different populations and to conduct meta-
regression analysis. Sensitivity analyses did not alter our findings. In selecting a far 
broader range of studies than previous meta-analyses, there is a risk that true treatment 
effects become harder to detect. However, our findings produced low overall 
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 heterogeneity, which limited the ability of our meta-regression analyses to detect 
potential covariates of varying response, such as insulin resistance and weight loss. It 
should be stressed that the I
2
 value is an estimate of heterogeneity that can be imprecise, 
particularly in smaller meta-analyses (53).Thus our calculated I
2
 of 0% heterogeneity 
does not mean there is no heterogeneity between studies. The use of averages of patient 
characteristics instead of individual patient data for meta-regression may have resulted 
in ecological fallacy and further limited power to detect relationships (54). We accepted 
small trials in our inclusion criteria, although exclusion of these studies did not affect the 
overall result. Across studies, glycaemia was generally a secondary outcome, such that 
trials were not specifically powered to detect a significant change in glycaemia. Finally, 
the majority of studies were judged as having an unclear risk of bias in at least one 
domain, mostly due to lack of explicit intention-to-treat analysis and lack of detail on 
allocation concealment procedures.  
 
Conclusion 
Selective serotonin reuptake inhibitors, in particular fluoxetine and 
escitalopram/citalopram, have a positive overall effect on glycaemia, which is 
incompletely explained by effects on depression or weight loss across studies. Powered 
clinical trials of fluoxetine and other SSRIs of longer duration are now needed to 
confirm these findings, whilst also studying the underlying mechanisms.  
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 FIGURE LEGENDS 
Figure 1 
PRISMA flow diagram summarising the literature search and study selection 
 
Figure 2 
Forest plot showing random effects meta-analysis of change in glycaemia for selective 
serotonin reuptake inhibitors versus placebo: stratified by medication type 
 
Figure 3 
Forest plot showing random effects meta-analysis of change in glycaemia for selective 
serotonin reuptake inhibitors versus placebo: stratified by diabetes status at baseline 
 
Figure 4 
Forest plot showing random effects meta-analysis of change in glycaemia for selective 
serotonin reuptake inhibitors versus placebo: stratified by depression status at baseline 
 
Figure 5 
Funnel plot to test publication bias. ‘g’ represents Hedge‟s g; this was used for effect 
size estimates.  
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 Table 1  
Summary characteristics of studies included in quantitative synthesis  
Citation, 
Country of 
setting 
 
Study 
design 
Total 
sample 
size 
(male), 
mean 
age  
Intervention 
(n), dose and 
duration 
Control (n) 
and duration 
Psychological 
inclusion 
criteria   
Baseline 
diabetes 
status; other 
metabolic 
status 
Mean 
baselin
e BMI 
(kg/  
) 
HOMA
-IR 
baseline 
HOMA
-Β 
baseline 
(%) 
Was 
glycaemic 
control a 
primary 
or 
secondary 
outcome?  
 
 
Citalopram or escitalopram 
Kamarck et 
al. (2011), 
US 
Double-
blind, 
placebo-
159 
(79), 
N/R 
Citalopram 
(n = 81), 
40mg/d for 2 
Placebo (n = 
78) for 2 
months  
High hostility 
(anger) scores 
on 
No selection  29.53 
(5.64) 
3.64 
(3.67) 
172.75 
(N/R) 
Primary 
outcome  
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 controlle
d RCT 
months  questionnaire
s  
Vander Wal, 
Gang, 
Griffing and 
Gadde 
(2012), 
US 
Double-
blind, 
placebo-
controlle
d RCT 
40 (19), 
45.00 
(13.02) 
Escitalopra
m (n = 20), 
20mg/d for 
12 weeks  
Placebo (n = 
20) for 12 
weeks 
Night Eating 
Syndrome 
(NES), ≥ 25 
on NES-
questionnaire 
No selection 32.95 
(6.92) 
N/R N/R Secondar
y 
outcome  
Glintborg et 
al. (2018), 
Denmark 
Double-
blind, 
placebo-
controlle
d RCT 
39 (0), 
31.00 
(6.00) 
Escitalopra
m (n = 20), 
20mg/d for 
12 weeks 
Placebo (n = 
19) for 12 
weeks 
None No selection; 
but selected 
for overweight 
premenopausa
l women with 
Polycystic 
Ovary 
35.80 
(6.50) 
4.80 
(2.40) 
229.00 
(126.00
) 
Secondar
y 
outcome  
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 Syndrome 
 
Fluoxetine 
Breum, 
Bjerre, Bak, 
Jacobsen 
and Astrup 
(1995),  
Denmark 
 
Double-
blind, 
placebo-
controlle
d RCT 
40 (12),  
43.95 
(9.27) 
Fluoxetine 
(n = 20), 
60mg/d for 
12 months  
Placebo (n = 
20) for 12 
months  
None T2DM or 
Impaired 
glucose 
tolerance 
(WHO criteria 
1985); obesity 
 
38.20 
(4.60) 
8.98 
(N/R) 
103.64 
(N/R) 
Secondar
y 
outcome  
Connolly et 
al. (1995), 
UK 
Double-
blind, 
placebo-
controlle
24 (15), 
65.91 
(N/R) 
Fluoxetine 
(n = 11), 
60mg/d for 6 
months 
Placebo (n = 
13) for 6 
months 
None Diet-
controlled 
T2DM 
(HbA1c 
31.73 
(N/R) 
N/R N/R Secondar
y 
outcome  
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 d RCT <14%) 
 
Daubresse 
et al. (1996), 
Belgium  
 
Double-
blind, 
placebo-
controlle
d RCT 
82 
(N/R),  
52 
(10.42) 
Fluoxetine 
(n = 39), 
60mg/d for 8 
weeks  
Placebo (n = 
43) for 8 
weeks  
None  T2DM; 
obesity 
34.24 
(4.85) 
9.72 
(N/R) 
68.12 
(N/R) 
Secondar
y 
outcome  
Kutnowski 
et al. (1992), 
Belgium
a
 
Double-
blind, 
placebo-
controlle
d RCT 
50 
(N/R), 
50.52 
(10.76) 
Fluoxetine 
(n = 25), 
60mg/d for 8 
weeks 
Placebo (n 
=25) for 8 
weeks 
None Impaired 
glucose 
tolerance 
(Oral glucose 
tolerance test, 
120 min blood 
glucose > 
6.7mmol/L) 
34.35 
(4.60) 
N/R N/R Secondar
y 
outcome  
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Lustman, 
Freedland, 
Griffith and 
Clouse 
(2000),  
US 
Double-
blind, 
placebo-
controlle
d RCT 
54 (16), 
46.35 
(12.25) 
Fluoxetine 
(n = 27), 
40 mg/d for 
8 weeks  
Placebo (n = 
27) for 8 
weeks 
Major 
depressive 
disorder, ≥ 14 
on BDI or 
HAM-D  
T2DM and 
minority 
T1DM 
 
 
N/R N/R N/R Secondar
y 
outcome  
Maheux, 
Ducros, 
Bourque, 
Garon and 
Chiasson 
(1997), 
Canada 
Double-
blind, 
placebo-
controlle
d RCT 
 
12 (8), 
54.5 
(11.09) 
Fluoxetine 
(n = 6), 
60mg/d for 4 
weeks 
Placebo (n = 
6) for 4 weeks 
None T2DM; 
obesity  
33.20 
(6.52) 
15.65 
(N/R) 
94.23 
(N/R) 
Secondar
y 
outcome  
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 O‟Kane, 
Wiles and 
Wales 
(1994),  
UK  
Double-
blind, 
placebo-
controlle
d RCT 
19 (6), 
57.13 
(N/R) 
Fluoxetine 
(n = 9), 
60mg/d for 
12 months  
Placebo (n = 
10) for 12 
months  
None  T2DM; 
obesity 
 
 
36.27 
(N/R) 
N/R N/R Secondar
y 
outcome  
Visser, 
Seidell, 
Koppeschaa
r and Smits 
(1993), 
Netherlands  
Double-
blind, 
placebo-
controlle
d RCT 
38 (38), 
40.6 
(6.79) 
Fluoxetine 
(n = 18), 
60mg/d for 
12 weeks 
Placebo (n 
=20) for 12 
weeks 
None  No selection 
for diabetes; 
but selected 
for obesity 
and high 
abdominal fat 
distribution  
27.9 
(1.17) 
2.17 
(N/R) 
89.26 
(N/R) 
Secondar
y 
outcome  
 
Fluvoxamine 
Lu, Chen, Double- 85 (61), 50mg/d Placebo with None; but No selection N/R 2.14 84.98 Secondar
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 Kuo, Hsu 
and Chen 
(2017),  
Taiwan  
 
blind, 
placebo-
controlle
d RCT 
44.88 
(8.98) 
Fluvoxamin
e with 
100mg/d 
clozapine (n 
= 43) for 12 
weeks 
(combinatio
n therapy) 
300 mg/d 
clozapine (n = 
42) for 12 
weeks 
(monotherapy
) 
selected for 
schizophrenia  
(DSM-IV) 
(1.98) (N/R) 
 
y 
outcome  
 
Paroxetine  
Paile-
Hyvärinen, 
Wahlbeck 
and 
Eriksson 
Single-
blind, 
placebo-
controlle
d RCT 
13 (0), 
61.65 
(10.04)  
Paroxetine 
(n = 7), 
20mg/d for 
10 weeks 
Placebo (n = 
6) for 10 
weeks 
Mild 
depression 
(MADRS 
2.5-12) 
T2DM 
(HbA1c < 
6.5%) 
30.91 
(4.81) 
N/R N/R Primary 
outcome  
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 (2003),  
Finland 
Paile-
Hyvärinen, 
Wahlbeck 
and 
Eriksson 
(2007), 
Finland  
Double-
blind, 
placebo-
controlle
d RCT 
43 (33), 
59.34 
(5.69) 
Paroxetine 
(n = 20), 
20mg/d for 6 
months  
Placebo (n = 
23) for 6 
months  
Mild 
depression 
(no more than 
6 symptoms, 
DSM-IV) 
T2DM 
(HbA1c > 
7.0%) 
31.84 
(5.41) 
N/R N/R Primary 
outcome  
Xue (2004), 
China
b
 
Double-
blind, 
placebo-
controlle
d RCT 
48 (20), 
Could 
not be 
acquire
d 
 
Paroxetine 
(n = 24), 
40mg/d for 8 
weeks 
Placebo (n = 
24) for 8 
weeks 
Major 
depressive 
disorder 
T2DM and 
minority 
T1DM 
 
N/R N/R N/R Secondar
y 
outcome 
Copyright © 2019 by the American Psychosomatic Society. Unauthorized reproduction of this article is prohibited.
AC
CE
PT
ED
  
Sertraline 
Echeverry, 
Duran, 
Bonds, Lee 
and 
Davidson 
(2009), 
US 
Double-
blind, 
placebo-
controlle
d RCT 
89 (24), 
52.5 
(9.00)  
Sertraline (n 
= 45), 
50mg/d to 
100mg/d for 
6 months 
Placebo (n = 
44) for 6 
months 
Major 
depressive 
disorder  
T2DM and 
minority 
T1DM 
N/R N/R N/R Primary 
outcome  
Notes: Data is presented as mean, with the standard deviation in parenthesis, unless indicated otherwise. Abbreviations: BDI, Beck‟s Depression 
Inventory; DSM-IV, Diagnostic and Statistical Manual of Mental Disorder (4
th
 edition); HAM-D, Hamilton Rating Scale for Depression; 
MADRS, Montogomery-Asberg‟s Depression Rating Scale; N/R, not reported; N/S, not significant. a) Glucose-intolerant subset of study 
analysed only, due to potential overlap between the diabetes subset in the study by Daubresse et al. (1996). b) The study by Xue (2004) was 
published in Chinese; as translation could not be acquired, data extraction was limited. 
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Table 2 
Risk of Bias in included studies, evaluated by the Cochrane Collaboration tool  
 
 
First 
author, 
Year, 
Country, 
 
 
Random 
sequence 
generation 
(selection bias) 
 
Allocation 
concealmen
t (selection 
bias) 
 
Blinding of 
participants 
and 
researchers 
(performanc
e bias) 
 
Blinding of 
outcome 
assessment 
(detection 
bias) 
 
Incomplete 
outcome data 
(attrition bias) 
 
Selective 
reporting bias 
(reporting 
bias) 
 
Other bias  
 
Summary 
assessment of 
risk of bias for 
the whole 
study 
 
 
Citalopram or escitalopram 
Kamarck, 
2011, US 
Low risk 
Randomised 
Low risk 
Central 
Low risk 
Blinding of 
Low risk 
Blinding of 
Low risk  
ITT analysis; 
Low risk  
All 
Unclear risk  
Participation 
Low risk  
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 allocation 
using a 
omputer 
generated 
randomisation 
list 
pharmacy-
controlled 
allocation, 
with 
concealmen
t of 
allocation 
in a 
confidential 
envelope 
  
participants 
and key 
study 
personnel 
outcome 
assessment 
ensured, and 
unlikely that 
blinding 
could have 
been broken 
all drop-outs 
were reported 
and reasons 
were stated 
predetermine
d outcomes 
were reported 
bias due to a 
potential 
difference 
between 
volunteers and 
those who did 
not return the 
postcard 
Vander 
Wal, 2012, 
US 
Low risk 
Randomised 
allocation 
using 
Low risk 
Central 
pharmacy-
controlled 
Low risk 
Blinding of 
participants 
and key 
Low risk 
Blinding of 
outcome 
assessment 
Low risk 
ITT analysis; 
no patients 
dropped out 
Low risk  
All 
predetermine
d outcomes 
Unclear risk  
Participants were 
recruited from 
those responding 
 Low risk  
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 computer-
generated 
block 
randomisation 
allocation  study 
personnel 
ensured, and 
unlikely that 
blinding 
could have 
been broken 
from the study were reported to 
advertisements- 
participation bias 
 
Glintborg, 
2018, 
Denmark 
Unclear risk 
Randomisation 
reported but 
method not 
described 
Low risk 
Central 
pharmacy-
controlled 
allocation  
Low risk 
Blinding of 
participants 
and key 
study 
personnel 
Low risk 
Blinding of 
outcome 
assessment 
ensured, and 
unlikely that 
blinding 
could have 
been broken 
High risk 
Although 
reasons for 
drop-outs were 
defined, ITT 
was not 
conducted  
Low risk  
All 
predetermine
d outcomes 
were reported 
Unclear risk 
Funded by 
Lundbeck and 
Novo Nordisk 
pharmaceutical 
companies 
Unclear risk  
Involvement 
of 
pharmaceutica
l companies 
and lack of 
ITT analysis 
may influence 
results 
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Fluoxetine 
Breum, 
1995, 
Denmark  
Unclear risk 
Randomisation 
reported but 
method not 
described 
Unclear 
risk 
Unknown 
Low risk 
Blinding of 
participants 
and key 
study 
personnel 
Low risk 
Blinding of 
outcome 
assessment 
ensured, and 
unlikely that 
blinding 
could have 
been broken 
Unclear risk  
Unknown if 
ITT analysis 
was 
performed, but 
did report 
drop-outs and 
reasons 
Low risk  
All 
predetermine
d outcomes 
were reported 
Unclear risk 
Funded by Eli 
Lilly and Co 
(pharmaceutical 
company) 
Unclear risk 
Involvement 
of 
pharmaceutica
l companies 
and lack of 
ITT analysis 
may influence 
results 
 
Connolly, 
1995, UK 
Unclear risk 
Randomisation 
reported but 
Unclear 
risk 
Unknown 
Low risk  
Double-
blind 
Low risk  
Double-
blind 
High risk  
Although the 
reasons for 
Low risk  
All 
predetermine
Unclear risk 
Funded by Lilly 
industries 
Unclear risk 
Involvement 
of 
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 method not 
described 
drop-outs were 
defined, they 
were excluded 
from analysis 
d outcomes 
were reported 
 
(pharmaceutical 
company) 
pharmaceutica
l companies 
and lack of 
ITT analysis 
may influence 
results 
 
Daubresse, 
1996, 
Belgium  
Unclear risk 
Randomisation 
reported but 
method not 
described 
Unclear 
risk 
Unknown 
Low risk 
Blinding of 
participants 
and key 
study 
personnel 
Low risk 
Blinding of 
outcome 
assessment 
ensured, and 
unlikely that 
blinding 
could have 
High risk 
Asymmetry in 
the reasons for 
drop-outs and 
intention to 
treat-analysis 
not performed.  
Low risk  
All 
predetermine
d outcomes 
were reported 
 
Unclear risk  
Unclear how the 
participants were 
recruited  
Unclear risk  
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 been broken 
Kutnowski, 
1992, 
Belgium  
Low risk 
„Randomisatio
n was balanced 
by blocks of 4‟ 
Unclear 
risk 
Unknown 
Low risk  
Double-
blind 
Low risk  
Double-
blind 
Low risk 
ITT analysis; 
all drop-outs 
and reasons 
were stated 
Low risk  
All 
predetermine
d outcomes 
were reported 
 
Unclear risk  
Eli Lilly 
Benelux 
provided the 
drugs and 
monitored with 
assistance 
Unclear risk 
Involvement 
of 
pharmaceutica
l company 
may positively 
influence the 
results with 
fluoxetine 
Lustman, 
2000, USA 
Low risk 
Randomised 
allocation 
using computer 
Unclear 
risk 
Unknown 
Low risk 
Blinding of 
participants 
and key 
Low risk 
Blinding of 
outcome 
assessment 
Low risk  
Although ITT 
analyses was 
not 
Low risk  
All 
predetermine
d outcomes 
Unclear risk  
Eli Lilly Indiana 
funded this study  
Low risk 
Involvement 
of 
pharmaceutica
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 generated 
randomisation 
study 
personnel 
ensured, and 
unlikely that 
blinding 
could have 
been broken 
implemented, 
no significant 
differences 
between 
completers 
and non 
completers of 
study; all 
drop-outs and 
reasons were 
defined  
were reported 
 
l company 
may positively 
influence the 
results with 
fluoxetine 
Maheux, 
1997, 
Canada 
Unclear risk 
Randomisation 
occurred but 
method not 
Unclear 
risk 
Unknown 
Low risk 
Blinding of 
participants 
and key 
Low risk  
Blinding of 
outcome 
assessment 
Unclear risk 
Unclear 
whether ITT 
analysis was 
Low risk  
All 
predetermine
d outcomes 
Unclear risk  
Eli Lilly Canada 
funded this study  
Unclear risk  
Involvement 
of 
pharmaceutica
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 described  study 
personnel 
ensured, and 
unlikely that 
blinding 
could have 
been broken 
implemented, 
or whether 
there were any 
drop-
outs/exclusion
s from 
analysis 
were reported 
 
l companies, 
lack of ITT 
analysis and 
lack of 
defining drop-
outs may 
influence 
results 
 
O‟Kane, 
1994, UK 
Unclear risk 
Randomisation 
occurred but 
method not 
described  
Unclear 
risk 
Unknown 
Low risk  
Double-
blind 
Low risk  
Double-
blind 
High risk  
Three 
participants 
dropped out, 
however ITT 
analysis was 
Low risk  
All 
predetermine
d outcomes 
were reported 
 
Unclear risk  
Lilly industries 
funded this 
study.  
Unclear risk  
Involvement 
of 
pharmaceutica
l companies 
and lack of 
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 not 
implemented. 
Reasons for 
drop-outs were 
specified. 
ITT analysis 
may influence 
results 
 
Visser, 
1993, 
Netherland
s  
Unclear risk 
Randomisation 
occurred but 
method not 
described 
Unclear 
risk 
Unknown 
Low risk  
Double-
blind 
Low risk  
Double-
blind 
High risk  
Two 
participants 
dropped out, 
reasons were 
stated but ITT 
analysis was 
not 
implemented 
Unclear risk  
Did not report 
adverse 
effects, 
although this 
was a pre-
specified 
outcome 
 
Unclear risk  
One of the 
authors was 
from Eli Lilly 
Netherlands. 
Unclear risk 
Involvement 
of 
pharmaceutica
l companies 
and lack of 
ITT analysis 
may influence 
results 
 
Copyright © 2019 by the American Psychosomatic Society. Unauthorized reproduction of this article is prohibited.
AC
CE
PT
ED
  
Fluvoxamine  
Lu, 2017, 
Taiwan  
Low risk 
Randomised 
allocation 
using computer 
generated 
stratified block 
randomisation  
Low risk 
Central 
computer-
generated 
allocation 
of 
treatment, 
with 
treatment 
delivered in 
coded 
containers.  
Low risk 
Blinding of 
participants 
and key 
study 
personnel 
Low risk  
Blinding of 
outcome 
assessment 
ensured, and 
unlikely that 
blinding 
could have 
been broken 
Low risk  
ITT analysis; 
all drop-outs 
and reasons 
were stated 
Low risk   
All 
predetermine
d outcomes 
were reported 
 
Low risk   Low risk  
Paroxetine 
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 Paile-
Hyvärinen, 
2003, 
Finland 
Low risk 
Randomised 
allocation 
using computer 
generated 
randomisation  
Unclear 
risk 
Allocation 
reported to 
have been 
concealead, 
but the 
method of 
concealmen
t was not 
adequately 
described  
Low risk  
Blinding of 
participants 
and 
clinicians, 
but not 
investigators
.  
High risk  
Investigator
s were not 
blinded- so 
may have 
introduced 
detection 
bias 
High risk 
No ITT 
analysis, as 2 
drop-outs not 
included in 
analysis; 
although 
reasons were 
defined 
Low risk   
All 
predetermine
d outcomes 
were reported 
 
Unclear risk 
Did not state 
exactly how the 
researchers 
recruited 
participants; 
possible 
participation bias  
Unclear risk  
Paile-
Hyvärinen, 
2007, 
Low risk 
Randomised 
allocation 
Low risk 
Central 
pharmacy-
Low risk 
Blinding of 
participants 
Low risk  
Blinding of 
outcome 
High risk   
ITT analysis 
not 
Low risk   
All 
predetermine
Unclear risk  
GlaxoSmithKlin
e funded the 
Unclear risk  
Involvement 
of 
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randomisation  
controlled 
allocation 
and key 
study 
personnel 
assessment 
ensured, and 
unlikely that 
blinding 
could have 
been broken 
implemented 
as only those 
who 
completed 
study were 
analysed; 
although 
reasons for 
drop-out were 
defined 
d outcomes 
were reported 
 
study and 
provided the 
drugs; 
competing 
interest   
pharmaceutica
l companies 
and lack of 
ITT analysis 
may influence 
results 
 
 
Sertraline 
Echeverry, 
2009, USA 
Low risk 
Randomised 
allocation 
Unclear 
risk   
Allocation 
Low risk 
Blinding of 
participants 
Low risk  
Blinding of 
outcome 
Low risk 
ITT analysis 
and  reasons 
Low risk   
All 
predetermine
Low risk   Low risk  
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 using computer 
generated 
randomisation  
reported to 
have been 
concealead, 
but the 
method of 
concealmen
t was not 
adequately 
described 
and key 
study 
personnel 
assessment 
ensured, and 
unlikely that 
blinding 
could have 
been broken 
for drop-outs 
were defined  
d outcomes 
were reported 
 
  
Notes: The risk of bias for each domain, with reasons, has been presented in this table. If the summary risk of bias was unclear, a justification 
was given. Abbreviations: ITT, Intention To Treat.  
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 Table 3 
Changes in glycaemia, weight, and adverse effects, following treatment with Selective Serotonin Reuptake Inhibitors compared to control groups 
 
Study author, 
year and country 
 
Intervention vs. 
control group 
 
Change in 
glycaemia for 
intervention 
group (SD) 
 
Change in 
glycaemia for 
placebo group (SD) 
 
P-value for 
comparing change in 
glycaemia between 
intervention and 
placebo groups 
 
Measure 
of 
glycaemi
c control 
 
Change in 
weight in 
SSRI group 
(kg) 
 
Adverse 
effects
a
 
 
Citalopram or escitalopram 
Kamarck, 2011, 
US 
 
Citalopram vs 
Placebo 
-0.13 (N/R) 
mmol/L 
+0.08 (N/R) 
mmol/L 
p = 0.020 FBG -0.26  N/S 
Vander Wal, 
2012, US 
Escitalopram vs 
Placebo 
+0.22 (0.35) 
mmol/L 
+0.42 (0.26) 
mmol/L 
p = 0.577 FBG -0.43  N/S 
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 Glintborg, 2018, 
Denmark 
Escitalopram vs 
Placebo 
0.00 (0.70) 
mmol/L 
 
0.00 (0.60) mmol/L p = N/S FBG N/R N/S 
 
Fluoxetine studies  
Breum, 1995, 
Denmark 
Fluoxetine vs 
Placebo 
-2.10 (3.60) 
mmol/L 
 
-0.80 (1.20) 
mmol/L 
p = N/R FBG -10.1 N/S 
Connolly, 1995, 
UK 
Fluoxetine vs 
Placebo 
-0.80 (3.48) 
mmol/L 
 
+1.20 (1.63) 
mmol/L 
p = N/S FBG -3.9  
 
N/S 
Daubresse, 1996, 
Belgium 
Fluoxetine vs 
Placebo 
-1.70 (2.83) 
mmol/L 
 
-0.02 (2.97) 
mmol/L 
p < 0.001 FBG -3.1  Significantly 
more patients 
experienced 
tremor in 
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 fluoxetine 
group 
 
Kutnowski, 1992, 
Belgium
b 
 
Fluoxetine vs 
Placebo 
-0.12 (0.55) 
mmol/L 
-0.03 (0.59) 
mmol/L 
p = N/S FBG N/R N/R for 
subgroup 
analysed 
Lustman, 2000, 
USA 
Fluoxetine vs 
Placebo 
-0.40 (1.65) % - 0.07 (1.65) % 
 
p = 0.130 HbA1c +6.09  N/S 
Maheux, 1997, 
Canada 
 
 
Fluoxetine vs 
Placebo 
-1.10 (2.79) 
mmol/L 
-0.40 (3.92) 
mmol/L 
p = N/S FBG -0.5  N/S 
O‟Kane, 1994, 
UK 
Fluoxetine vs 
Placebo 
-0.30 (1.78) 
mmol/L 
-0.50 (1.78) 
mmol/L 
p = N/S FBG N/R N/S 
Visser, 1993, Fluoxetine vs -0.02 (0.19) -0.12 (0.27) p = N/S FBG -5.9  N/R 
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 Netherlands 
 
Placebo mmol/L mmol/L 
 
Fluvoxamine studies  
Lu, 2017, Taiwan Fluvoxamine and 
clozapine vs 
Placebo and 
clozapine 
 
-0.02 (0.73) 
mmol/L 
 
+0.50 (1.11) 
mmol/L 
p < 0.001 FBG +0.7  N/S 
 
Paroxetine studies  
Paile-Hyvärinen, 
2003, Finland 
Paroxetine vs 
Placebo 
-1.47 (2.52) 
mmol/L 
-0.78 (0.58) 
mmol/L 
p = 0.720 FBG -0.71  N/R 
Paile-Hyvärinen, 
2007, Finland 
Paroxetine vs 
Placebo 
-0.20 (3.56) 
mmol/L 
+0.10 (3.65) 
mmol/L 
p = N/R FBG -0.5  N/R 
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Xue, 2004, China Paroxetine vs 
Placebo 
-0.50 (1.49) % -0.10 (1.60) % p = N/S HbA1c N/R N/R 
 
Sertraline studies  
Echeverry, 2009, 
USA 
Sertraline vs 
Placebo 
-2.00 (2.10) % -0.90 (2.00) % p = 0.003 
 
HbA1c -0.045  N/R 
 
Notes: Data are presented as mean, with the standard deviation in parenthesis, unless indicated otherwise. Abbreviations: FBG; Fasting blood 
glucose; HbA1c, glycosylated haemoglobin; N/R, not reported; N/S, not significant; SD, standard deviation; vs., versus. a) Adverse effects only 
reported when there was a significantly greater incidence in the intervention group compared to control group. b) Glucose-intolerant subset of study 
analysed only due to potential overlap between the diabetes subset in the study by Daubresse et al. (1996). 
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